Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic <i>EGFR</i>-Mutated, <i>MET</i>-Amplified NSCLC Patient With Acquired <i>MET</i> Y1230H Mutation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.